• Neurologix Inc., of Fort Lee, N.J., received additional financing from three of its largest investors: Corriente Advisors, GE Pension Trust and Palisade Capital Management LLC. Those investors provided a loan to the company in the aggregate principal amount of $7 million. Funds will go toward NLX-P101, an adeno-associated virus vector gene therapy for Parkinson's disease. Neurologix said it will seek additional funding to support a pivotal Phase III trial.

• Sagent Pharmaceuticals Inc., of Schaumburg, Ill., filed for an initial public offering, aiming to raise up to $100 million. The specific terms and timing have not yet been disclosed. The specialty pharma firm expects to use proceeds from the offering for general corporate purposes, including working capital, product development and operating expenses. Upon completion of the IPO, Sagent would trade on Nasdaq under the ticker "SGNT."